June 11, 2020

Acquisitions of companies involved in the medical devices business fall under the Italian foreign investment control

More than 2 months ago the Italian Government issued certain measures[1] with the purpose of expanding its power to veto or impose conditions on acquisitions of, or other transactions involving, Italian targets operating in certain strategic sectors.

Recently[2] the abovementioned measures have been converted into Law and have been partially amended in the conversion process.

One of the amendments consists of specifying that, on a temporary basis (i.e. until the issuance of the relevant implementing decrees), acquisitions of controlling stakes in Italian target companies operating in business of production, import and wholesale distribution of medical devices, medical/surgical devices and personal protective devices must be notified to the Italian Government under the foreign investment control regime.

We note that the same clarification has not been made with respect to those provisions (included in the same set of measures) aimed specifically at hindering the COVID-19 emergency which expand/strengthen significantly the Italian Government’s control power (providing duties to notify acquisitions of controlling stakes also by EU acquirors, etc.) until December 31, 2020.

For more information please see our article on “The Expansion of Italian Foreign Investment Control in the COVID-19 era” available at this link.

[1] Articles 15 and following of Law Decree no. 23 of April 8, 2020.

[2] By means of Law no. 40 of June 5, 2020.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on